Key Highlights
- Shares are up 2.87% pre-market to $86.52, building on last week's roughly 7-12% surge.
- The rally follows a legal Patent win and strong early Demand for the company's new Atera platform, with 2026 Revenue guidance raised to $610 million to $630 million.
- The stock is pushing to fresh 52-week highs, aided by a wave of bullish analyst resets.
10x Genomics (NASDAQ:TXG) shares are up 2.87% pre-market to $86.52, building on last week's roughly 7-12% surge, as investors continue to digest a legal patent win, strong early demand for the company's new Atera platform, and momentum from raised full-year 2026 revenue guidance of $610 million to $630 million. The stock is pushing to fresh 52-week highs near $86, aided by a wave of bullish analyst resets, including UBS lifting its target to $68 from $20, and renewed enthusiasm around AI-enabled genomics tools.
The rally comes even as the underlying Business remains unprofitable, with second-quarter revenue down 12.6% year-over-year and continued operating losses. The company's core Chromium platform enables single-cell gene expression, immune profiling, and multiome analyses, while its Visium and Xenium platforms provide spatial gene expression and protein co-detection capabilities, serving academic, government, biopharmaceutical, and biotechnology customers globally.
Analyst Sentiment Shifts Sharply Higher
The scale of the recent analyst price-target increases stands out against the stock's underlying financial picture, suggesting the market is pricing in a turnaround narrative built around the new Atera platform and AI-enabled genomics demand rather than near-term profitability. Founded in 2012 and headquartered in Pleasanton, California, the company has established itself as a leading provider of tools for single-cell and spatial biology research.
FAQs
Q: Why is 10x Genomics stock rising pre-market today?
A: Shares are extending a multi-day rally as investors digest a recent legal patent win, strong early demand for the new Atera platform, and raised full-year revenue guidance.
Q: How much did the company raise its 2026 revenue guidance?
A: Full-year 2026 revenue guidance was raised to a range of $610 million to $630 million.
Q: Is the company currently profitable?
A: No. The underlying business remains unprofitable, with second-quarter revenue down 12.6% year-over-year and continued operating losses.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.